SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 9, 2018--
Exelixis,
Inc. (NASDAQ: EXEL) today announced that renowned biomedical
research executive Maria C. Freire, Ph.D. has been elected to the
company’s Board of Directors. Dr. Freire’s appointment took effect on
April 5, 2018.
Dr. Freire has three decades of leadership experience with prominent
national and global health organizations. She currently serves as
President and Executive Director and as a member of the board of
directors of the Foundation for the National Institutes of Health
(FNIH), an independent 501(c)(3) charitable organization established by
Congress to support the mission of the National Institutes of Health
(NIH) by raising private funds for biomedical research and fostering
partnerships and alliances around the world. Dr. Freire was previously
President and a member of the board of directors of The Albert and Mary
Lasker Foundation and, before that, President and CEO of the Global
Alliance for TB Drug Development.
“I’m pleased to welcome Dr. Maria Freire to the Exelixis board of
directors,” said Stelios Papadopoulos, Ph.D., an Exelixis co-founder and
chairman of the company’s board. “Her breadth of experience in
biomedical research and development can benefit Exelixis greatly as the
company recommits its resources to drug discovery and bolstering its
pipeline following the successful ongoing commercialization of its lead
medicine, CABOMETYX.”
Dr. Freire began her current position as President and Executive
Director of the FNIH in November 2012. From March 2008 to November 2012,
she served as President of The Albert and Mary Lasker Foundation. Prior
to joining the Lasker Foundation, Dr. Freire served as President and CEO
of the Global Alliance for TB Drug Development from 2001 to 2008 and
from 1995 to 2001, she served as Director of the Office of Technology
Transfer at the NIH. Dr. Freire currently serves on the board of
directors of Alexandria Real Estate Equities, Inc., a publicly-held
urban office real estate investment trust uniquely focused on
collaborative life science and technology campuses. She has served on
the boards of numerous national and international organizations,
including the Science Board of the U.S. Food and Drug Administration,
the World Health Organization Commission on Intellectual Property
Rights, Innovation and Public Health, Gavi, the Vaccine Alliance and the
United Nations Secretary General’s High Level Panel on Access to
Medicines. Dr. Freire is also a member of the National Academy of
Medicine and the Council on Foreign Relations. She is the recipient of
numerous awards, including a 2017 Gold Stevie Award for “Woman of the
Year,” the U.S. Department of Health and Human Services Secretary’s
Award for Distinguished Service, the Arthur S. Fleming Award and the
Bayh-Dole Award. Dr. Freire holds a Ph.D. in Biophysics from the
University of Virginia and a B.S. from the Universidad Peruana Cayetano
Heredia in Lima, Peru.
About Exelixis
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our lead
compounds, cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring these medicines to
patients globally. We are steadfast in our commitment to prudently
reinvest in our business to maximize the potential of our pipeline. We
intend to supplement our existing therapeutic assets with targeted
business development activities and internal drug discovery – all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis recently earned a spot on
Deloitte’s Technology Fast 500 list, a yearly award program honoring the
500 fastest-growing companies over the past four years. For more
information about Exelixis, please visit www.exelixis.com,
follow @ExelixisInc
on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis and the Exelixis logo are registered U.S. trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180409006372/en/
Source: Exelixis, Inc.
Investors Contact:
Exelixis, Inc.
Susan
Hubbard, 650-837-8194
Executive Vice President, Public
Affairs & Investor Relations
shubbard@exelixis.com
or
Media
Contact:
For Exelixis, Inc.
Hal
Mackins, 415-994-0040
hal@torchcommunications.com